The preparation for phaeochromocytoma surgery is a matter of debate. Pre-operative blockade of a-1 receptors is increasingly employed in an attempt to reduce the risk of hypertensive episodes, especially during manipulation of the tumour. In this study, we compared the interest of an almost complete blockade of these receptors by high doses of urapidil in comparison with that of moderate doses of this drug. The study was conducted in two consecutive series of 18 patients, the first treated by a moderate dose, and the second by the highest dose tolerated by the patient. The two groups were comparable in other respects. All patients were operated under laparoscopy by the same surgeon and managed by the same anaesthetist using the same protocol. The number of hypertensive peaks was significantly reduced using the high dose of urapidil, with no more hypotensive episodes after tumour removal in this group. The area under the curve of norepinephrine levels as a function of time was significantly larger with the high doses of urapidil, arguing in favour of a more complete blockade of a-1 receptors. Our findings indicate the value of aggressive blockade of a-1 receptors in preparation for surgery of phaeochromocytoma.
Introduction
Phaeochromocytoma is treated by surgery, which unfortunately exposes the patient to a risk of severe hypertensive episodes 1, 2 triggered by the liberation of large amounts of catecholamines during manipulation of the tumour and even from peritoneal insufflation in the laparoscopic approach. Current practice involves pre-surgical preparation of patients by a blockade of a-1 receptors. The agent employed depends largely on the experience of the surgical team, and the doses used appear somewhat arbitrary. 3 We examined here whether an almost complete blockade of a-1 receptors designed to reduce the consequences of excessive liberation of catecholamines might improve the haemodynamic stability both during and after surgery. We utilized an intravenous infusion of a selective and competitive a-1 receptor blocker, urapidil, 4, 5 an easily manipulated agent with a short half-life. This agent is thus well suited for pre-operative preparation, enabling rapid adaptation to haemodynamic variations with a short weaning period, thus reducing the risk of post-operative hypotension. 6, 7 We compared in a consecutive and prospective manner the interest of an arbitrary and usual dose of this agent to the maximum dose tolerated by the patient in preparation to resection of a phaeochromocytoma.
Materials and methods
This study took place in two consecutive phases: from 1998 to 2001, all patients with phaeochromocytoma underwent a pre-operative preparation over 3 days by i.v. urapidil at a dose of 10-15 mg h À1 , the objective being a supine systolic arterial pressure (SAP) below 135 mm Hg; from 2002 to 2006, a preparation using the maximum dose tolerated by the patient, the limiting factor being dizziness or symptoms of orthostatic hypotension.
Patients
All patients included in this study had an adrenal phaeochromocytoma confirmed by assay of urinary metanephrine and normetanephrine, adrenal computed tomography scan and I-metaiodobenzyguanidine scintigraphy. In all cases, the diagnosis was confirmed by histologic analysis of the tumour removed. All patients gave their consent to this study.
Pre-operative preparation
In most cases, patients had been prepared at least 10 days before surgery by prazozin GITS, 5-10 mg per day, and a b-blocker when necessary. Three days before the operation, all oral antihypertensive treatments were stopped and an intravenous drip of urapidil was set up. The treatment was started at a dose of 5 mg h À1 and increased in steps of 1 mg h À1 every hour. In the first group, the objective was an SAP below 135 mm Hg and the doses did not exceed 20 mg h À1 . In the second group, the dose was increased until the appearance of dizziness or a standing SAPp90 mm Hg. In the event of symptoms or orthostatic hypotension, the dose of urapidil was returned to the previous tolerated dose. This dose was then maintained until operation. All patients received normal salt diet.
Anaesthesia and surgery
All anaesthesia were performed by the same physician (PTF) using the same procedure. 7 Briefly, after radial artery cannulation, general anaesthesia was induced using i.v. propofol 2 mg kg Àl and sufentanil 0.8 mg kg
Àl . Tracheal intubation was facilitated with cisatracurium 0.15 mg kg
Àl
. Anaesthesia was maintained with end-tidal isoflurane or sevoflurane concentrations of 1.5-2.5%, respectively, and with a continuous infusion of sufentanil 30-40 mg h
Àl . The patients were mechanically ventilated with 100% oxygen, and ventilation was adjusted to keep end-tidal PCO 2 between 4.7 and 6.0 kPa. Isotonic saline or Ringer's lactate solution was infused intraoperatively at a rate of 10-15 ml kg Àl h À1 . All patients were operated by laparoscopy by the same surgeon (PB). The procedure was divided into five periods and blood samples were removed for assay of norepinephrine during each period: before induction of anaesthesia (T0), after the inductionlaryngoscopy-orotracheal intubation sequence (T1), at the end of peritoneal insufflation (T2), during adrenal gland manipulation (T3), after gland resection (T4) and in the recovery room when the trachea was extubated and the patient was haemodynamically stable (T5). Hypertensive peaks (SAP4160 mm Hg) were treated with i.v. boluses of nicardipine 2-4 mg to maintain the SAP between 120 and 160 mm Hg. Intravenous boluses of esmolol 1-1.5 mg kg Àl were used if the heart rate exceeded 100 b.p.m. Hypotensive episodes (SAPo80 mm Hg) were treated with i.v. boluses of ephedrine 3-6 mg.
Statistical analysis
Data were analysed using the Sigmaplot (version 10) statistical package (Systat Software, Point Richmond, CA, USA). The distribution of each variable was checked for normality using the KolmogorovSmirnov test. In our earlier study with low doses of urapidil, the incidence of hypertensive episodes during tumour resection was 66%. 7 Assuming that it would decrease to 56% with high doses, 18 patients in each group were required for the paired t-test with a ¼ 0.05, b ¼ 0.1 (power: 90%) and standard deviation ¼ 12%. Categorical data were compared using w 2 and Fisher's exact tests where appropriate. The Friedman repeated-measures analysis of variance one rank and Dunn's post hoc tests were used for the comparisons within groups. Student's t-test or Mann-Whitney tests were employed where appropriate for the comparisons between groups.
Results
We included 18 patients in each group. There were no significant differences between the two groups in age, size of the phaeochromocytoma, urinary excretion of methoxylated derivatives over 24 h and duration of the surgical procedure (Table 1) . During the different phases of surgery and especially in the times most exposed to hypertensive episodes (insufflation of the peritoneum and manipulation of the tumour), the systolic pressure tended to be lower in the group treated with high doses of urapidil, but when estimated at each time the differences were not significant ( Table 2 ). The hypertensive episodes and tachycardia were observed essentially during insufflation and during manipulation of the tumour. The number of blood pressure peaks observed 7.9 ± 5.6 9.1 ± 8.1 NS Preparation for surgery of phaeochromocytoma P Gosse et al during peritoneal insufflation (T2) and the number of episodes of tachycardia were significantly higher in the group treated with low doses of urapidil (Table 3 ). There were no differences in the number of hypotensive episodes. No severe complications were observed in either group and no hypoglycemia. There were marked inter-individual differences in norepinephrine levels, which also fluctuated considerably during the operation (Figure 1 ). We observed a significantly (Po0.05) larger area under the curve of median levels of norepinephrine in the group treated with a high dose of urapidil ( Figure 2 ).
Discussion
There is now widespread implementation of preoperative preparation by a-blocking for excision of phaeochromocytoma. This preparation is designed to reduce hypertensive episodes triggered by the release of catecholamines during the various stages of both conventional and laparoscopic surgery.
There are three periods when blood pressure can swing wildly: peritoneal insufflation and manipulation of the tumour can give rise to hypertensive episodes and tachycardia as a result of catecholamine release. Removal of the tumour can lead to shock due to an abrupt fall in circulating catecholamines.
Various agents and protocols have been described in the literature. The sole criteria of validation are haemodynamic stability and the absence of complications. The relative rarity of phaeochromocytoma explains why published series tend to be small with few comparative studies. 8 An additional problem derives from the marked inter-individual differences in severity and incidence of clinical manifestations of phaeochromocytoma. This stems largely from the marked variability in the secretion of catecholamines from one patient to another and at different times. Under such conditions, it is not easy to propose a management strategy to an individual patient using fixed doses of the blocking agent. Doses employed have tended to be arbitrary, based on the observed modification of seated or supine blood pressure.
We hypothesized that the extent of the release of catecholamines by the tumour during surgery and the haemodynamic consequences would depend on the magnitude of the blockade of a-1 receptors before the operation. We therefore attempted to induce the highest blockade compatible with an absence of orthostatic hypotension as a-adrenergic tonus plays an important role in the maintenance of standing blood pressure. As a complete blockade might increase the risk of hypotension after the removal of the tumour, we infused intravenously an a-blocking agent with a short duration of action. Abbreviations: HR, heart rate; SAP, systolic arterial pressure. T0: before induction of anaesthesia; T1: after induction-laryngoscopy-orotracheal intubation sequence; T2: at the end of peritoneal insufflation; T3: during adrenal gland manipulation; T4: after gland resection; T5: in the recovery room when the trachea was extubated and the patient was haemodynamically stable.
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In addition, urapidil possesses a weak blocking action on b-1 receptors, which reduces the risk of tachycardia. 9 Since we have used systematic preparation by urapidil 7 we have noted that hypertensive peaks were transitory and readily responded to low-dose nicardipine i.v. Similarly, the fall in blood pressure on removal of the tumour is transitory and responds to low ephedrine i.v.
Our results showed a lower incidence of hypertensive episodes in the group treated with high doses of urapidil compared with the group treated with low doses. This difference was significant despite the small sample size. The lower occurrence of tachycardia probably stemmed from the weak b-blocking action of urapidil. There was no greater incidence of hypotension in the group treated with high doses. The increase of the area under the curve of norepinephrine levels in the group treated with high doses of urapidil might be attributed to a higher secretion from tumours in this group, although this was thought unlikely as the two groups were comparable despite the absence of randomization. The difference could also have stemmed from reduction in negative feedback from circulating catecholamines on the secretion of the phaeochromocytoma. This was ruled out as this type of feedback has not been described in phaeochromocytoma in which secretion and liberation of catecholamines appear to be out of control. 10 We assumed it to have been due to saturation of a-1 receptors by urapidil, which would lead to an increase in the amounts of circulating norepinephrine. This increase in the area under the curve of norepinephrine was interpreted as a pharmacological validation of optimal blockade of a-1 receptors.
Limitations of the study. The main limitations of our study are the absence of randomization and the small sample size. The rarity of this tumour made it impossible in our centre so we tested large doses of urapidil after a good experience with moderate doses. Surgeon, anaesthesist and procedures were kept the same for the two groups. However, we cannot exclude that any difference between groups may be due to other factors than pre-operative treatment. This study can therefore be considered as a pilot one and may contribute to trigger in the future a multicentric randomized trial with larger sample.
The preparation of patients before surgery of a phaeochromocytoma is the subject of debate. Although a-blockade would appear to be a logical procedure for these patients, some have suggested that it is ineffective, 11 whereas others consider that it increases the risk of post-operative hypotension and prefer the use of calcium antagonist. [12] [13] [14] The largest series with a-blockade to date has been conducted with phenoxybenzamine, 15-17 a noncompetitive and non-selective blocker of a-1 and -2 receptors that may expose patients to post-operative hypotension. Prazosine and doxazosin, competitive and selective inhibitors of a-1 receptors, have also been widely used. 3 Among proponents of a pathophysiological approach and pre-operative a-blockade, there are divergences of opinion on the duration and extent of this blockade. To our knowledge, our study is the first to try to provide an objective answer to this question. Our results argue in favour of an almost complete blockade of a receptors providing optimal haemodynamic stability (blood pressure and heart rate) without increasing the risk of post-operative hypotension. Clearly, reduction in hypertensive episodes during surgery is not the most important criterion for evaluating the safety of such a pre-operative preparation. To date and since adopting this mode of preparation we have not had any occurrences of serious events and no mortality over a total of 40 procedures. As the mortality of surgery of phaeochromocytoma is now around 1%, [18] [19] [20] it is still too early to conclude on the value of this pre-operative preparation by urapidil. However, this preliminary study, which T1 T2 T3 T4 T5 Figure 2 Area under the curves of the median norepinephrine levels at the different stages of surgical procedure. AUC: area under the curve; T0: before induction of anaesthesia; T1: after induction-laryngoscopy-orotracheal intubation sequence; T2: at the end of peritoneal insufflation; T3: during adrenal gland manipulation; T4: after gland resection; T5: in the recovery room when the trachea was extubated and the patient was haemodynamically stable.
What is known about this topic K In phaeochromocytoma surgery, pre-operative blockade of a-1 receptors is increasingly employed in an attempt to reduce the risk of hypertensive episodes, especially during manipulation of the tumour. K However, doses employed have tended to be arbitrary.
What this study adds
K Our results argue in favour of almost complete blockade of a receptors with i.v. urapidil providing optimal haemodynamic stability (blood pressure and heart rate) without increasing the risk of post-operative hypotension.
Preparation for surgery of phaeochromocytoma P Gosse et al is in line with pathophysiological principles, is encouraging.
